XJPX4599
Market cap121mUSD
Jan 23, Last price
306.00JPY
1D
0.66%
1Q
-12.29%
IPO
-68.83%
Name
StemRIM Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.20%
Rev. gr., 5y
63.68%
Revenues
0k
-100.00%
Net income
-2.02b
L
CFO
-1.88b
L
Earnings
Mar 11, 2025
Profile
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | 2018‑07 | 2017‑07 | |
| Income | ||||||||
Revenues | 2,350,000 10,128.06% | 22,976 -98.36% | ||||||
Cost of revenue | 1,481,993 | 2,800,393 | 2,003,663 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (1,481,993) | (450,393) | (1,980,687) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 3,000 | 1,856 | 2,082 | |||||
Tax Rate | ||||||||
NOPAT | (1,484,993) | (452,249) | (1,982,769) | |||||
Net income | (2,022,000) -1,301.07% | 168,350 -108.64% | (1,948,306) 234.50% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 79,498 | 205,744 | 115,920 | |||||
BB yield | -0.29% | -0.36% | -0.23% | |||||
| Debt | ||||||||
Debt current | 1,062 | 3,141 | ||||||
Long-term debt | 531 | 4,203 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | 108,381 | 108,209 | 108,035 | |||||
Net debt | (8,424,449) | (10,254,171) | (8,931,847) | |||||
| Cash flow | ||||||||
Cash from operating activities | (1,881,497) | 1,135,315 | (1,404,565) | |||||
CAPEX | (2,000) | (350) | (332) | |||||
Cash from investing activities | (4,784) | (344) | (330) | |||||
Cash from financing activities | 78,966 | 202,602 | 112,859 | |||||
FCF | (1,826,776) | (100,536) | (2,007,426) | |||||
| Balance | ||||||||
Cash | 8,410,449 | 10,217,764 | 8,880,191 | |||||
Long term investments | 14,000 | 38,000 | 59,000 | |||||
Excess cash | 8,424,449 | 10,138,264 | 8,938,042 | |||||
Stockholders' equity | (529,066) | 1,358,893 | (1,215,198) | |||||
Invested Capital | 9,531,981 | 9,120,836 | 10,728,219 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 61,317 | 62,531 | 59,189 | |||||
Price | 449.00 -51.51% | 926.00 10.24% | 840.00 26.70% | |||||
Market cap | 27,531,268 -52.45% | 57,903,411 16.46% | 49,718,645 29.05% | |||||
EV | 19,106,819 | 47,649,240 | 40,786,798 | |||||
EBITDA | (1,437,644) | (402,608) | (1,931,214) | |||||
EV/EBITDA | ||||||||
Interest | 58 | 140 | ||||||
Interest/NOPBT | ||||||||